RUTHERFORD, N.J., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, announced today that Panna Sharma, President and Chief Executive Officer of Cancer Genetics, will provide a corporate overview at the BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City on February 10-11, 2014.
|BIO CEO Presentation|
|Date:||Tuesday, February 11, 2014|
|Time:||2:00pm Eastern Time|
|Location:||Waldorf Astoria Hotel, East Foyer Room, 3rd Floor|
About the BIO CEO and Investor Conference
The BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives can meet and have the opportunity to shape the future investment landscape of the biotechnology industry. This year's conference will feature presentations from more than 150 established public and private biotech companies and non-profit funding organizations. Approximately 1,400 delegates are expected to attend including 700 finance and investment professionals.
About Cancer Genetics
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended September 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Investor Relations Michael Rice Life Science Advisors LLC 646-597-6979 Media Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 email@example.comSource:Cancer Genetics